BioCentury
ARTICLE | Financial News

Synthetic lethality company Ideaya raises $94M

March 16, 2018 4:58 PM UTC

Ideaya Biosciences Inc. (South San Francisco, Calif.) raised $94 million in a series B round on March 15 led by Nextech Invest, 6 Dimensions Capital, BVF Partners and Perceptive Advisors. Fellow new investors GV, Roche Venture Fund, Boxer Capital of the Tavistock Group and Driehaus Capital joined existing investors 5AM Ventures, Canaan Partners, Celgene Corp. (NASDAQ:CELG), WuXi Healthcare Ventures and Alexandria Venture Investments in the round (see BioCentury, March 15).

CEO Yujiro Hata told BioCentury the financing should provide the synthetic lethality and immuno-oncology company with runway through 2H21...